Assembly of a Functional HCV Glycoprotein Heterodimer

Muriel Lavie, Anne Goffard, and Jean Dubuisson*

Institut de Biologie de Lille (UMR8161), CNRS, Université de Lille I and II, and Institut Pasteur de Lille, Lille, France

Abstract
The two HCV envelope glycoproteins E1 and E2 are released from HCV polyprotein by signal peptidase cleavages. These glycoproteins are type I transmembrane proteins with a highly glycosylated N-terminal ectodomain and a C-terminal hydrophobic anchor. After their synthesis, HCV glycoproteins E1 and E2 associate as a noncovalent heterodimer. The transmembrane domains of HCV envelope glycoproteins play a major role in E1/E2 heterodimer assembly and subcellular localization. The envelope glycoprotein complex E1/E2 has been proposed to be essential for HCV entry. However, for a long time, HCV entry studies have remained limited because of the lack of a robust cell culture system to amplify this virus. A few years ago, a model mimicking the entry process of HCV lifecycle has been developed by pseudotyping retroviral particles with native HCV envelope glycoproteins. This model allowed the characterization of functional E1/E2 envelope glycoproteins. The data obtained can now be confirmed with the help of a newly developed cell-culture system that allows efficient amplification of HCV (HCVcc). Here, we present the recent data that have now been accumulated on the assembly of the functional HCV glycoprotein heterodimer.

Introduction
As obligate intracellular parasites, all viruses must have ways of entering target cells to initiate replication and infection. The first step in virus entry is the recognition of host cells through cell surface receptor(s). This initial engagement can both mediate attachment and act as a primer for subsequent conformational alteration, leading to virus entry into host cell. In many cases, interaction with a receptor is important for defining the tropism of a virus for a particular organism, tissue or cell type. Enveloped viruses possess a lipid bilayer that surrounds their nucleocapsid. The glycoproteins present in their envelope are involved in the receptor-binding step. After attachment, the entry of these viruses into cells requires the fusion of the viral and a cellular membrane by a process that is also driven by the viral envelope glycoproteins. To fulfill these functions, viral envelope glycoproteins have to adopt dramatically different conformations during the virus lifecycle. In addition, these conformational changes have to occur at a precise time of the virus lifecycle and have thus to be tightly controlled.

HCV encodes two envelope glycoproteins, called E1 and E2. For a long time, the lack of a cell culture system supporting efficient HCV replication and particle assembly has hampered the characterization of the envelope proteins present on the virion. Cell culture transient expression systems have allowed the characterization of the first steps in the biogenesis of HCV envelope glycoproteins (reviewed in Op De Beeck et al., 2001). In addition, surrogate models have also been developed to study the entry steps of HCV lifecycle (reviewed in Op De Beeck and Dubuisson, 2003). Among them, HCVpp has been developed by pseudotyping retroviral particles with native HCV envelope glycoproteins and has allowed to characterize the assembly of functional HCV envelope glycoproteins (Bartosch et al., 2003b; Drummer et al., 2003; Hsu et al., 2003). More recently, the development of a cell-culture system that allows a relatively efficient amplification of HCV permits to confirm the data previously obtained and to study the role played by the envelope proteins during the whole life cycle of HCV (Lindenbach and Rice, 2005; Wakita et al., 2005; Zhong et al., 2005).

Biogenesis of HCV envelope glycoproteins

Cleavage of HCV glycoproteins from the polyprotein
As for the other members of the Flaviviridae family the genome of HCV encodes a single polyprotein. This ~3010 amino acid polyprotein is processed by cellular (signal peptidase and signal peptide peptidase) and viral proteases (NS2–3 and NS3–4A) to generate at least 10 polypeptides (reviewed in Penin et al., 2004). The nonstructural proteins are released from the polyprotein after cleavage by HCV proteases NS2–3 and NS3–4A, whereas the structural proteins are released by host endoplasmic reticulum (ER) signal peptidase(s) (Fig. 1) (reviewed in Reed and Rice, 2000). Further processing mediated by a signal peptide peptidase also occurs at the C-terminus of the capsid protein (McLauchlan et al., 2002). Although most cleavages in the polyprotein precursor proceed to completion during or immediately after translation, partial cleavages at the E2/p7 and p7/NS2 sites lead to the production of an uncleaved E2p7NS2 molecule (Dubuisson et al., 1994; Dubuisson and Rice, 1996; Grakoui et al., 1993; Lin et al., 1994; Mizushima et al., 1994). Most of NS2 is progressively cleaved from the E2p7NS2 precursor, whereas at least for most HCV strains analyzed, the cleavage between E2 and p7 does not change over time (Dubuisson, 2000). This leads to the production of E2, E2p7, p7 and NS2.

The sequences located immediately N-terminally of E2/p7 and p7/NS2 cleavage sites can efficiently function as signal peptides. Indeed, when fused to a reporter protein, the signal peptides of p7 and NS2 are efficiently cleaved (Carrère-Kremer et al., 2004). These data indicate that inefficiency of cleavage at E2/p7 and p7/NS2 sites is...
shown that p7 reconstituted into artificial lipid membranes is supposed to be tightly regulated. It has recently been will likely play their role in virion assembly, a process that replication (Blight et al., 2005). These data suggest that p7 can potentially adopt a dual transmembrane topology. It contains two viral strains has identified a difference of three amino acids and mutational analysis has shown that the V720L mutation of some glycosylation sites in the context to be occupied by glycans (Goffard et al., 2003; Slater-Handshy et al., 2004). In addition, the short distance not due to the presence of suboptimal signal peptides. The p7 polypeptide is a polytopic membrane protein containing two transmembrane domains with both its N- and C-termini oriented toward the ER lumen (Fig. 1) (Carrère-Kremer et al., 2002). Interestingly, the presence of the first transmembrane domain of p7 reduces the efficiency of p7/NS2 cleavage (Carrère-Kremer et al., 2004). Sequence analyses and mutagenesis studies have also identified structural determinants responsible for the partial cleavage at both E2/p7 and p7/NS2 sites (Carrère-Kremer et al., 2004). In addition, the short distance between the cleavage site of E2/p7 or p7/NS2 and the predicted transmembrane α-helix located downstream of the cleavage sites might impose additional structural constraints to these cleavage sites (Fig. 1). Such constraints in the processing of a polypeptide precursor are likely essential for HCV to post-translationally regulate the kinetics and/or the level of expression of p7 as well as NS2 and E2 mature proteins.

The processing at the E2p7 site has been further explored. It has been reported to be more efficient in genotype 1b (strain BK) than in the genotype 1a (strain H77c) (Dubuisson et al., 1994; Lin et al., 1994). A sequence comparison of p7 signal peptides of these two viral strains has identified a difference of three amino acids and mutational analysis has shown that the V720L change in the H77c sequence substantially increases the efficiency of processing at the E2/p7 site (Isherwood and Patel, 2005). Although, when expressed alone, p7 protein has been shown to adopt a double membrane spanning topology with both extremities oriented luminally in the ER (Carrère-Kremer et al., 2002), the C-terminal part of E2p7 proteins has been found to be located in the cytosol (Isherwood and Patel, 2005). These data suggest that p7 can potentially adopt a dual transmembrane topology. It remains however to be shown whether an E2p7 with a cytosolic orientation of the C-terminus of p7 exists when this protein is expressed in the context of the polyprotein.

Since p7 and NS2 are not essential for HCV genomic replication (Blight et al., 2000; Lohmann et al., 1999), they will likely play their role in virion assembly, a process that is supposed to be tightly regulated. It has recently been shown that p7 reconstituted into artificial lipid membranes homo-oligomerizes and behaves as an ion channel protein (Griffin et al., 2003; Griffin et al., 2004; Pavlovic et al., 2003; Premkumar et al., 2004). It is likely that, when bound to E2, p7 cannot oligomerize and function as an ion channel, and the existence of E2p7 would therefore reduce the amount of functional p7 molecules available. Production of precursors like E2p7NS2 and E2p7 might be a means to maintain p7 inactive during the phase of the accumulation of E2 molecules required for HCV envelope formation. Alternatively, such precursors might also control the temporal release of E2 and NS2.

Glycosylation of HCV envelope glycoproteins

N-linked glycosylation is one of the most common types of protein modification, and it occurs by the transfer of an oligosaccharide from a lipid intermediate to an Asn residue in the consensus sequence Asn-X-Thr/Ser of a nascent protein, where X is any amino acid except Pro (Gavel and von Heijne, 1990; Kornfeld and Kornfeld, 1985). The addition of this glycan is catalyzed by the oligosaccharyltransferase, which is closely associated with the translocon through which the nascent peptide chains emerge in the ER lumen (Silberstein and Gilmore, 1996). However, not every tripeptide sequence in a protein sequence is used for carbohydrate addition (Gavel and von Heijne, 1990). In the early secretory pathway, the glycans play a role in protein folding, quality control and certain sorting events. Viral envelope proteins usually contain N-linked glycans that can play a major role in their folding, in their entry functions or in modulating the immune response (Hebert et al., 1997; Ohuchi et al., 1997a; Ohuchi et al., 1997b; van Kooyk and Geijtenbeek, 2003; von Messling and Cattaneo, 2003; Wei et al., 2003).

The ectodomains of HCV envelope glycoproteins E1 and E2 are highly modified by N-linked glycans. E1 and E2 possess up to 6 and 11 potential glycosylation sites, respectively (Fig. 2). Sequence analyses of E1 indicate that five potential N-glycosylation sites are strongly conserved among HCV genotypes (Goffard and Dubuisson, 2003; Zhang et al., 2004b). However in one case the presence of a proline residue immediately downstream the glycosylation site is unfavorable for glycosylation, and it has been confirmed experimentally that this site is not glycosylated (Meunier et al., 1999). Interestingly, the glycosylation site of E1 at position 250 is poorly conserved; this site is indeed only observed in genotypes 1a and 1b (strain H77c) (Dubuisson et al., 1994; Lin et al., 1994). In the context of the H

Mutants of E1 and E2 have been produced to characterize the glycosylation of these proteins (Goffard et al., 2005; Meunier et al., 1999; Nakano et al., 1999; Slater-Handshy et al., 2004). In the context of the H strain, the four potential glycosylation sites were shown to be occupied by glycans (Goffard et al., 2005; Meunier et al., 1999). In the case of E2, a first study has shown that mutation of some glycosylation sites in the context...
of a truncated form of E2 alters the recognition by sera from HCV patients (Nakano et al., 1999); however, these mutants were not characterized in terms of glycosylation and no clear conclusion can be drawn from this study. More recently, glycosylation mutants have been produced in the context of a truncated form of E2 ending at position 660 (Slater-Handshy et al., 2004). The E2 sequence of HCV isolate used in this study contains 10 instead of 11 potential glycosylation sites, the site N5 at position 476 being missing (Fig. 2). Interestingly, the last two glycosylation sites, N10 and N11, were not occupied in E2(660) (Slater-Handshy et al., 2004). However, at least one of these sites was occupied in the context of full-length E2. A more recent mutagenesis study, in the context of an E2 glycoprotein containing 11 potential glycosylation sites, has shown that all the sites are occupied by glycans (Goffard et al., 2005). In this case, E2 was expressed as a polyprotein containing full-length E1 and E2. Altogether, these data indicate that full-length and truncated forms of E2 can have different properties.

The addition of the glycan precursor is catalyzed by the oligosaccharyltransferase, and this enzyme is thought to have access only to nascent chains as they emerge from the ribosome at the luminal face of the rough ER (Silberstein and Gilmore, 1996). The glycosylation process of HCV envelope glycoprotein E1 has been analyzed in the context of a Man-P-Dol-deficient cell line (B3F7) and it has been shown to occur post-translationally (Duvet et al., 2002), indicating that the oligosaccharyltransferase has also access to the E1 glycoprotein for more than an hour after its translation. A characterization of HCV glycoprotein E1 has also shown that, in the absence of E2, different glycoforms of E1 are produced and the glycosylation of E1 is improved by co-expression of E2 in cis (Dubuisson et al., 2000).

**Folding of HCV envelope glycoproteins**

HCV envelope glycoproteins have been shown to assemble as a noncovalent E1E2 heterodimer (Deleersnyder et al., 1997). However, at least in heterologous expression systems, HCV envelope glycoproteins have a tendency to also form misfolded aggregates stabilized by disulfide bonds (reviewed in Dubuisson, 2000). Analyses of HCV envelope glycoproteins with conformation-sensitive antibodies are therefore necessary to discriminate noncovalent heterodimers from misfolded complexes (Cocquerel et al., 2003b; Deleersnyder et al., 1997). Alternatively, such discrimination can also be made by analyzing disulfide-bond formation by migrating HCV envelope glycoproteins on SDS-PAGE under non-reducing conditions (Brazzoli et al., 2005; Dubuisson and Rice, 1996). Analyses of the formation of conformation-dependent epitopes and disulfide-bond formation indicate that folding of HCV envelope glycoproteins is a slow process (Brazzoli et al., 2005; Deleersnyder et al., 1997; Dubuisson and Rice, 1996; Duvet et al., 1998). Interestingly, the folding of E1 has been shown to be dependent on the co-expression of E2 (Michalak et al., 1997; Patel et al., 2001). In addition, it has also been shown that the folding of E2 is also dependent on the co-expression of E1 (Michalak et al., 2003a; Coquerel et al., 2003a). Altogether, these observations indicate that HCV envelope glycoproteins cooperate for the formation of a functional complex. These observations also indicate that, although some degree of folding can be observed in E2 expressed alone (Coquerel et al., 2003a; Michalak et al., 1997), both glycoproteins need to be co-expressed to analyze their functional properties.

During their folding, HCV envelope glycoproteins have been shown to interact with calnexin (Brazzoli et al., 2005; Choukhi et al., 1998; Dubuisson and Rice, 1996).
1996; Merola et al., 2001), a lectin-like ER chaperone, which shows an affinity for monoglucosylated N-linked oligosaccharides (Trombetta and Helenius, 1998). Both E1 and E2 have been found to associate rapidly with calnexin and dissociate slowly, suggesting a role of this chaperone in the folding of HCV envelope glycoproteins (Choukhi et al., 1998; Dubuisson and Rice, 1996; Merola et al., 2001). However, more recent data suggest that only E1 interacts with calnexin (Brazzoli et al., 2005). Differences in the cell lines used and/or in the levels of expression of the envelope glycoproteins might potentially explain these discrepancies. Further experiments in cell cultures infected with native HCV particles will be needed to confirm the involvement of calnexin in the folding E2.

The presence of glycans on HCV envelope glycoproteins can potentially affect their folding either directly or through interaction with calnexin. Site-directed mutagenesis studies have indeed shown that the absence of some glycans in E1 (N1 and N4) and E2 (N8 and N10) leads to misfolding of HCV envelope glycoproteins (Fig. 2) (Goffard et al., 2005; Meunier et al., 1999). This alteration in folding was not due to the lack of interaction of HCV envelope glycoproteins with calnexin, suggesting that the mutations would rather have a direct effect on protein folding. The presence of a large polar saccharide is indeed known to affect the folding at least locally by orienting polypeptide segments toward the surface of protein domains (Imperiali and O’Connor, 1999; Wormald and Dwek, 1999).

Involvement of the transmembrane domains in the biogenesis of E1E2 heterodimer

Membrane anchor and signal sequence

Due to their resistance to alkaline or salt extraction, HCV envelope glycoproteins have been confirmed to be membrane associated proteins (Cocquerel et al., 2001; Ralston et al., 1993). In addition, deletion of the C-terminal hydrophobic regions of these proteins leads to their secretion, indicating that these regions are involved in membrane anchoring (Michalak et al., 1997). Sequence analysis of a large number of HCV isolates has shown that the C-termini of E1 and E2 contain hydrophobic sequences that are less than 30 amino acid residues long (Fig. 2) (Cocquerel et al., 2000). As in other viruses of the Flaviviridae family, these regions are composed of two stretches of hydrophobic residues separated by a short segment containing at least one fully conserved positively charged residue (Cocquerel et al., 2000). Interestingly, when fused to a reporter protein the second hydrophobic stretch functions as a signal sequence (Cocquerel et al., 2002), which is in agreement with the observation that HCV envelope glycoproteins are released from the polyprotein precursor after cleavage by host signal peptidase(s) (Dubuisson et al., 2002). It is worth noting that in the context of HCV polyprotein, only the sequence located at the C-terminus of the immature form of the capsid protein is a true signal peptide that will interact with the signal recognition particle (Santolini et al., 1994). The sequences present at the C-terminus of E1 and E2 do not interact with the signal recognition particle, and they should be called signals of reinitiation of translocation (Fig. 1). Deletion of these signals leads to the secretion of E1 and E2, indicating that these signals are involved in their membrane anchoring (Cocquerel et al., 2000).

ER retention function

HCV envelope glycoproteins are retained in the ER (Deleersnyder et al., 1997; Dubuisson et al., 1994; Duvet et al., 1998), and ER retention signals are present in the transmembrane domains of E1 and E2 (Cocquerel et al., 1999; Cocquerel et al., 1998). In addition, the charged residues of the transmembrane domains of E1 (Lys) and E2 (Asp and Arg) play a key role in the ER retention of these glycoproteins (Cocquerel et al., 2000). It has been proposed that an additional ER retention signal might also be present in the ectodomain of E1 (Mottola et al., 2000). Interestingly, in some conditions of overexpression a small fraction of HCV envelope glycoproteins has been shown to accumulate at the plasma membrane (Bartosch et al., 2003b; Drummer et al., 2003; Hsu et al., 2003; Op De Beeck et al., 2004). Cell surface expression of E1 and E2 is likely due to the accumulation of small amounts of glycoproteins escaping the ER-retention machinery, due to saturation of this mechanism. Importantly, the retention of E1E2 in the ER has been confirmed in HCVcc infected cells (Rouillé et al., 2006).

Role in heterodimerization

In addition to their anchoring, signal sequence and ER retention functions, the transmembrane domains of HCV envelope glycoproteins have also been shown to play a major role in the assembly of E1E2 heterodimer. Indeed, deletion of the transmembrane domain of E2 or its replacement by the anchor signal of another protein abolishes the formation of E1E2 heterodimer (Cocquerel et al., 1998; Michalak et al., 1997; Patel et al., 2001; Selby et al., 1994). Other studies by site-directed mutagenesis or alanine scanning insertion mutagenesis (Ciczora et al., 2005; Cocquerel et al., 2000; Op De Beeck et al., 2000) have confirmed that the transmembrane domains of E1 and E2 play a direct role in E1E2 assembly. In addition, alanine scanning insertion mutagenesis allowed to identify two distinct segments in the transmembrane domain of E1 and one in the transmembrane domain of E2 that were specifically involved in E1E2 assembly (Fig. 2). Interestingly, at least one region located outside of the transmembrane domains has also been shown to be involved in heterodimerization (Drummer and Poumbourios, 2004).

Topological change in the transmembrane domain of HCV glycoproteins

The topology of the transmembrane domain of HCV envelope glycoproteins has given rise to some controversy. Indeed the presence of a first hydrophobic stretch and a signal sequence function separated by charged residues in the transmembrane domains of E1 and E2 has suggested that they might be composed of two membrane spanning segments with the charged residues facing the cytosol (Charloteaux et al., 2002). This type of organization has been observed in the C-terminal region of the envelope glycoprotein E2 of the alphaviruses as well as for the envelope proteins of the flaviviruses (Op De Beeck et al., 2002).
et al., 2003; Strauss and Strauss, 1994; Zhang et al., 2003). However sequence analysis and data of alanine scanning insertion mutagenesis were in favor of a single spanning topology of E1 and E2 transmembrane domain (Cocquerel et al., 2000; Op De Beeck et al., 2000). A study of the topology of the transmembrane domains of HCV envelope glycoproteins has been performed by determining the accessibility of their N- and C-termini in selectively permeabilized cells (Cocquerel et al., 2002). This work has shown that before signal sequence cleavage at their C-terminus, the transmembrane domains form a hairpin structure (Fig. 1). However, after cleavage between E1 and E2 or between E2 and p7, the second C-terminal hydrophobic stretch is reoriented towards the cytosol, leading to the formation of a single membrane-spanning domain. Here again, the charged residues located in the middle of the transmembrane domains were shown to play a crucial role in their structural dynamics (Cocquerel et al., 2002).

Role of HCV envelope glycoproteins in virus entry
For most viruses, entry into the cytosol is a multistep process, during which the host cell assists the incoming virus. Viruses first attach themselves to components of the plasma membrane, which they use as non-specific attachment factors or as specific cell surface receptors. Viral attachment is mediated by the binding of a protein present at the surface of the virion to a molecule on the cell surface acting as a virus receptor. The envelope glycoprotein complex E1E2 is the viral component thought to be present at the surface of HCV particles and it is therefore the obvious candidate ligand for cellular receptors. Receptor binding can activate cellular endocytic pathways through which viruses are internalized in endosomes. When they reach the appropriate intracellular location, viruses are activated for penetration by cellular signals and make their way through the membrane of the endosome, or through the plasma membrane for those that do not enter by endocytosis. Enveloped viruses fuse their lipid envelope with the plasma membrane or the membrane of an endosome, resulting in the release of the nucleocapsid into the cytosol.

Models to study HCV entry
In the absence of a robust cell culture system to amplify HCV, several models have been developed to study HCV entry. In a first approach, a soluble form of HCV glycoprotein E2 has been used to identify cell surface proteins potentially involved in HCV entry (Pili et al., 1998; Rosa et al., 1996). Although this approach is potentially interesting in protein-protein interactions studies, it cannot be used to study the entire entry process. In addition, as discussed above, due to their cooperative role in folding, both glycoproteins need to be co-expressed to analyze their functional properties. To study the role of E1E2 envelope glycoproteins in HCV entry, several surrogate models of HCV particles have therefore been developed. As a first approach, virus-like particles have been produced in insect cells infected by a recombinant baculovirus containing the cDNA of HCV structural proteins (Baumert et al., 1998). However these particles are not infectious and they are retained in an intracellular compartment. It is therefore difficult to evaluate how close these virus-like particles are to native virion. In addition, due to the absence of infectivity, these particles cannot be used to study the fusion process. Another approach to study HCV entry has been to produce virosomes by incorporating E1E2 heterodimers into liposomes (Lambot et al., 2002). These virosomes can be used to study the interactions between E1E2 heterodimers and cell surface receptors. However, it has not been shown whether the envelope glycoproteins incorporated into these liposomes can induce fusion.

Other models have been based on pseudotyping of viral vectors. The first model that has been developed was based on vesicular stomatitis virus (VSV) pseudotyped with modified E1 and/or E2 glycoproteins (Lagging et al., 1998; Matsuura et al., 2001). In these particles, the transmembrane domains of HCV envelope glycoproteins have been replaced by the transmembrane domain and cytoplasmic tail of the VSV envelope glycoprotein G. This allows the export of HCV envelope glycoproteins to the cell surface (Takikawa et al., 2000). However, some doubts have been raised on the infectivity of such VSV pseudotyped particles (Buonocore et al., 2002). In addition, replacement of HCV envelope glycoproteins has been shown to alter their entry function (Hsu et al., 2003).

More recently, retroviruses have also been used to produce pseudotyped particles containing HCV envelope glycoproteins (Bartosch et al., 2003b; Drummer et al., 2003; Hsu et al., 2003). Murine leukemia virus (MLV) or human immunodeficiency virus (HIV) vectors were used. Retroviruses are indeed well known to be able to incorporate in their envelope a variety of cellular and viral glycoproteins (Ott, 1997; Sandrin et al., 2002). In addition, they can easily package and integrate genetic markers into host cell DNA (Negre et al., 2002). All these properties were exploited to produce viral pseudoparticles expressing E1E2 at their surface and packaging a reporter gene that allows the monitoring of viral infection. HCV pseudoparticles (HCVpp) are produced by transfecting 293T cells with three expression vectors encoding the E1E2 polyprotein, the retroviral core proteins and a packaging-competent retrovirus-derived genome containing a marker gene (Fig. 3). Because MLV and HIV are supposed to assemble at the plasma membrane and HCV glycoproteins are retained in the ER, a first approach has been to modify the transmembrane domains of E1 and E2 to re-address them at the plasma membrane (Hsu et al., 2003; Pohlmann et al., 2003). However pseudoparticles bearing such modified HCV envelope glycoproteins were not infectious. Surprisingly, in the absence of any modification of HCV envelope glycoproteins, infectious pseudoparticles were produced (Bartosch et al., 2003b; Drummer et al., 2003; Hsu et al., 2003). Interestingly, due to saturation of the ER retention machinery, the cells used to produce HCVpp were shown to express a small fraction of HCV envelope glycoproteins at the plasma membrane (Bartosch et al., 2003b; Drummer et al., 2003; Hsu et al., 2003; Op De Beeck et al., 2004). This accumulation at the plasma membrane might therefore be sufficient to incorporate native HCV envelope glycoproteins into retroviral pseudotyped particles. However, a recent study
has shown that the functional unit is a noncovalent conformation-sensitive neutralizing monoclonal antibodies characterization of HCVpp envelope glycoproteins with the HCV glycoproteins that initiate infection. However, the nature of E1 and E2 incorporated into HCVpp (Flint et al., 2003; Op De Beeck et al., 2004). This system is based on the transfection of the human hepatoma cell line HuH-7 with genomic HCV RNA of the genotype 2a JFH1 strain cloned from an individual with fulminant hepatitis. In order to allow comparative studies between different HCV strains, chimeric genomes encoding the structural proteins from different genotypes and the non-structural proteins from the JFH1 isolate have also been made (Pietschmann et al., 2006). The HCVcc system allows, for the first time, the study of the complete viral cycle life and is very helpful to confirm the data generated with HCVpp.

**HCV receptors**

As a first approach to identify potential HCV receptor(s), a soluble form of HCV glycoprotein E2 has been used. This allowed the identification of the CD81 tetraspanin (Levy and Shoham, 2005) as a putative receptor for HCV (Pili et al., 1998). A very similar approach identified the scavenger receptor class B type I (SR-BI) (Scarselli et al., 2002), a high-density lipoprotein (HDL)-binding molecule (Connelly and Williams, 2004), and the mannose binding lectins DC-SIGN and L-SIGN (van Kooyk and Geijtenbeek, 2003) as additional candidate receptors for HCV (Gardner et al., 2003; Lozach et al., 2003; Ludwig et al., 2004; Pohlmann et al., 2003). Heparan sulfate has also been shown to interact with HCV glycoprotein E2, suggesting that this type of molecule can play a role in HCV entry (Barth et al., 2003). An approach using virus-like particles produced in insect cells has led to the identification of the asialoglycoprotein receptor as another candidate receptor for HCV (Saunier et al., 2003). Very recently, claudin-1, a tight junction protein highly expressed in the liver, has been shown to be essential for HCV entry (M.J. Evans, T von Hahn, A.J. Syder, T. Hatzioannou, J.A. McKeating P. Bieniasz, C.M. Rice, 13th International Meeting on Hepatitis C virus and Related Viruses, Cairns, Australia, 27–31 August 2006). Finally, because of the physical association of HCV with low- or very-low-density lipoproteins (LDL or VLDL) in serum, the LDL receptor has also been proposed as another candidate receptor for HCV (Agnello et al., 1999; Monazahan et al., 1999).

A number of cell-surface molecules bind viral envelope glycoproteins without mediating entry, and validation of a viral receptor or co-receptor requires proof that the putative receptor is necessary for infection. This is not easy for HCV due to the absence of a robust cell culture system to amplify this virus. The development of HCVpp and more recently of HCVcc has allowed to further investigate the role of candidate receptors in virus entry. Among all the candidate receptors, CD81, Claudin-1 and SR-BI have been shown to play a direct role in HCVpp entry. Indeed, antibodies directed against CD81 or SR-BI as well as siRNA targeting CD81 or Claudin-1 reduce HCVpp or HCVcc infectivity (Bartosch et al., 2003b;
domains of HCV envelope glycoproteins have shown that some mutations can affect the entry function of HCVpp without alteration in the biogenesis of E1E2 heterodimer and their incorporation into HCVpp (Ciczora et al., 2005). This suggests that in addition to their role in E1E2 heterodimerization, the transmembrane domains of HCV glycoproteins might play a role in coordinating protein reorganization for the fusion process to occur.

Studies of E2-CD81 interactions and identification of epitopes recognized by antibodies that inhibit these interactions suggest that the CD81-binding region consists of discrete segments of E2 that are rearranged within the same domain during E2 folding (Clayton et al., 2002; Flint et al., 1999a; Forns et al., 2000a; Hsu et al., 2003; Owsianka et al., 2001; Yagnik et al., 2000). Interestingly, E2 residues critical for CD81 binding have recently been identified by site-directed mutagenesis (Drummer et al., 2006; Owsianka et al., 2006). They include amino acids W420, W437, L438, L441, F442, Y527, W529, G530 and D535.

Besides the CD81 binding region, the hypervariable region 1 (HVR1) (Weiner et al., 1991), a 27-amin acid long segment found at the N-terminus of E2 (Fig. 2), has also been suggested to play a role in cell attachment (Penin et al., 2001; Scarselli et al., 2002). This region evolves rapidly in infected individuals, suggesting that it is under strong immune pressure (reviewed in Mondelli et al., 2003). Although an HCV clone lacking HVR1 was shown to be infectious in chimpanzee, this mutant virus was attenuated, suggesting that HVR1 plays a facilitating role in HCV infectivity (Forns et al., 2000b). In addition, deletion of HVR1 reduces HCVpp infectivity (Bartosch et al., 2003c) and abolishes HDL-mediated enhancement of HCVpp infectivity (Voisset et al., 2005). Despite strong amino acid sequence variability related to strong pressure towards change, the chemico-physical properties and conformation of HVR1 are highly conserved, and HVR1 is a globally basic stretch, with basic residues located at specific sequence positions. Functional studies of HCVpp containing mutations in HVR1 indicate that infectivity increases with the number of basic residues in HVR1 (Callens et al., 2005). In addition, a shift in position of some charged residues modulates infectivity. These data suggest that HVR1 is a region involved in interaction with a host molecule involved in HCV entry.

HCV envelope glycoproteins are highly glycosylated and some maturation of these glycans has been observed on HCV envelope glycoproteins associated with HCVpp (Flint et al., 2004; Lozach et al., 2004; Op De Beeck et al., 2004). Mutation of some glycosylation sites in HCV envelope glycoproteins can reduce or abolish HCVpp infectivity without apparently affecting folding and incorporation of the glycoproteins into the particles (Goffard et al., 2005). N-linked glycans at position N2 and N4 of E2 have indeed been shown to be essential for the entry functions of HCV envelope glycoproteins (Fig. 2). In addition, some other glycans (N2 of E1 and N5, N6 and N11 of E2) can also modulate HCVpp entry. Further studies will be necessary to determine whether these mutations affect receptor binding or the fusion properties of HCV envelope glycoproteins. Interestingly, it has recently been shown that the interaction of lectin
cyanovirin-N with HCV envelope protein glycans leads to inhibition of HCV entry by inhibiting CD81-E2 interaction (Helle et al., 2006).

Mechanisms of HCV entry

Virus attachment to receptors initiates a series of events that lead to virus entry. For enveloped viruses, the entry process is controlled by viral surface glycoproteins that undergo triggered conformational changes from a metastable state to a lower energy state. This structural change leads to the exposure of a buried functional element, named the fusion peptide and is believed to provide the energy required for the merging of the lipid bilayers (reviewed in Colman and Lawrence, 2003). Until very recently, viral fusion proteins have been shown to fall into two different structural classes designated as class I and II (reviewed in Earp et al., 2005). Class I fusion proteins possess N-terminal or N-proximal fusion peptides, and they are synthesized as a precursor that is cleaved into two subunits by host cell proteases. In some cases (e.g. influenza HA), the two subunits remain associated through a disulfide bond, whereas in others (e.g. HIV Env) the two subunits remain associated through noncovalent interactions. The proteolytic processing event creates the metastable state of the fusion protein (Colman and Lawrence, 2003). In their native metastable conformation, class I fusion proteins form trimeric spikes at the surface of the virions with the fusion subunit being highly helical. Upon a fusion trigger event (receptor binding at the cell surface or low pH in endosomes), the trimeric proteins transiently form an extended conformation allowing the hydrophobic fusion peptide to insert into the target membrane. Protein refolding leads then to the formation of very stable trimeric structures in which both the N-proximal fusion peptide and the C-proximal membrane anchor are juxtaposed at the same end to allow virus and cell membrane connection and hemifusion (reviewed in Colman and Lawrence, 2003).

Class II viral fusion proteins have a completely different structure. They are predominantly non-helical, instead having a beta-sheet type structure; they are not cleaved during biosynthesis; and they possess an internal fusion peptide with a loop conformation (reviewed in Earp et al., 2005). The proteins are oriented parallel to the membrane, and they have a three-domain architecture with domain I beginning at the N-terminus, domain II containing the internal fusion loop, and domain III being at the C-terminus. In addition, class II fusion proteins are synthesized as a complex with a second membrane glycoprotein (prM for flaviviruses; pE2 for alphaviruses). Newly synthesized E and prM proteins of the tick-borne encephalitis virus associate to form noncovalent heterodimers (Fig. 4) that are incorporated into immature virions by budding into the ER lumen (Allison et al., 1995; Mackenzie and Westaway, 2001). These particles are then transported through the secretory pathway and shortly before release from the cell, the activation of the fusogenic potential occurs by the cleavage of the accessory protein prM by a cellular furin protease in the trans-Golgi network (Stadler et al., 1997). After prM cleavage, the E protein exists as a metastable homodimer at the virion surface. The ectodomains of the dimer are orientated antiparallel to one another (Modis et al., 2003; Rey et al., 1995). The architecture of the alphavirus Semliki Forest virus spike is similar to that of tick-borne encephalitis virus E, but in this case, the metastable oligomer is a heterodimer of the fusion protein E1 and the companion protein E2 with an associated small protein E3 (Modis et al., 2003; Rey et al., 1995). In addition, contrary to flaviviruses, alphavirus envelope proteins have been shown to bud from the plasma membrane.

It is worth noting that the notion of class I and II fusion proteins is more complex than previously thought. Indeed, the reported crystal structures of herpes simplex virus glycoprotein B and glycoprotein G of vesicular stomatitis virus have revealed multidomain trimers with features characteristic of both class I and class II fusion proteins (Heldwein et al., 2006; Roche et al., 2006).

Both alphaviruses and flaviviruses enter target cells by receptor-mediated endocytosis. The receptor recognition function is carried by the fusion protein itself for the flaviviruses (E) and by the companion protein (E2) for the alphaviruses. Exposure to the acidic pH of the endosomes triggers a major conformational change of the envelope involving dissociation of the native homodimer (for flaviviruses) or heterodimer (for alphaviruses) and the irreversible formation of homotrimers of the fusion proteins (Earp et al., 2005; Mukhopadhyay et al., 2005).

Based on its classification in the Flaviviridae family, HCV envelope has been proposed to contain a class II fusion protein (Yagnik et al., 2000). As found in the case of alphaviruses and flaviviruses, HCVpp and HCVcc entry depends on acidic pH and on clathrin-mediated endocytosis (Bartosch et al., 2003c; Blanchard et al., 2006;
Hsu et al., 2003; Koutsoudakis et al., 2006; Tscherne et al., 2006). Moreover, it has recently been shown that after internalization in clathrin-coated vesicles, HCVpp entry required the delivery to early endosomes (Meertens et al., 2006). However, we still do not know if the acidic pH of endosomes is sufficient to activate E1E2 and induce fusion or if other endosomal factors are required. Indeed, although acidic pH can induce HCVpp-liposome fusion without any preliminary priming event (Lavillette et al., 2006), it has been reported that HCVcc and HCVpp infection at the plasma membrane induced by a pH drop was very inefficient (Meertens et al., 2006; Tscherne et al., 2006). Characterization of the route of HCV entry needs further investigations. Contrary to what is observed for other class II envelope proteins, there is no evidence that HCV envelope glycoproteins are matured by a cellular endoprotease during their transport through the secretory pathway (Op De Beeck et al., 2004). In addition, HCV envelope glycoproteins are highly glycosylated, whereas other class II envelope proteins contain a very low number of glycans (Fig. 4). Interestingly, some of the glycans present on HCV envelope glycoproteins are involved in controlling HCV entry (Goffard et al., 2005).

There remains some controversy on the identity of HCV fusion protein. It has been proposed that E1 might be a good candidate because sequence analyses suggest that it might contain a putative fusion peptide in its ectodomain (Flint et al., 1999b; Garry and Dash, 2003). On the other hand, potential structural homology with other class II fusion proteins suggests that E2 could be the fusion protein (Yagnik et al., 2000). Mutagenesis studies in the putative fusion peptides of the envelope glycoproteins associated with HCVpp as described for the flavivirus envelope protein E (Allison et al., 2001), should be helpful for further characterization of HCV fusion protein. In addition, a high-resolution structure of HCV envelope glycoproteins would also help understanding the fusion mechanism of the virus.

Inhibition of HCV envelope glycoprotein functions by neutralizing antibodies

Because they are exposed at the surface of the virion, the envelope proteins are targets of neutralizing antibodies. These antibodies block a viral infection by inhibiting virion binding or membrane fusion. Understanding the mechanisms of neutralization needs therefore a good knowledge of the mechanism of entry. The role of neutralizing antibodies in HCV infection and disease progression remained unclear for a long time, largely because of the lack of assays to measure and quantify their activity. Previous experiments showed that serum from a chronically infected patient could neutralize HCV infectivity in a chimpanzee model, giving evidence for antibody-mediated neutralization of HCV (Farcì et al., 1994). Neutralizing antibodies could also be identified by their ability to prevent HCV replication in a lymphoid cell line (Shimizu et al., 1994; Shimizu et al., 1996).

The development of HCVpp and HCVcc offers the possibility to study HCV neutralization with defined sequences of HCV envelope glycoproteins, and the use of HCVpp and HCVcc in neutralization studies has been validated. As determined with HCVpp, it seems that the majority of chronically infected patients have cross-reactive neutralizing antibodies (Logvinoff et al., 2004; Meunier et al., 2005). In contrast, neutralizing antibodies have not been detected in several cases of acute resolving infection (Logvinoff et al., 2004; Meunier et al., 2005), and the detection of neutralizing antibodies in acutely infected individuals did not seem to be associated with viral clearance (Logvinoff et al., 2004). However, another study has shown in some patients a progressive emergence of a relatively strong neutralizing response in correlation with a decrease in viremia (Lavillette et al., 2005a). Further investigations on a large number of acutely infected patients will be necessary to determine the role of neutralizing antibodies in controlling HCV infections. Interestingly, it has been observed that HCVpp and HCVcc infectivity is enhanced by human sera, and this enhancement of infectivity can partly mask the presence of neutralizing antibodies (Dreux et al., 2006; Lavillette et al., 2005a; Meunier et al., 2005; Voisset et al., 2006). In addition, HDL have been identified as the component responsible for serum-mediated enhancement of infectivity (Bartosch et al., 2005; Meunier et al., 2005; Voisset et al., 2005) and have been shown to attenuate neutralization of HCV entry by monoclonal and HCV patient-derived antibodies (Dreux et al., 2006; Voisset et al., 2006). Attenuation of neutralization by HDL could be explained by a more rapid kinetic of HDL-facilitation of HCVpp entry compared to virus neutralization (Voisset et al., 2006).

For a long time, the HVR-1 sequence of E2 has been proposed to be a major target for neutralizing antibodies (Farcì et al., 1996; Kato et al., 1993). However, data obtained with the HCVpp model indicate that neutralizing epitopes located outside of HVR1 also exist (Bartosch et al., 2003a). Interestingly, characterization of HCVpp with monoclonal antibodies has allowed the identification of conformation-dependent and -independent neutralizing epitopes outside of HVR1 (Fig. 2) (Bartosch et al., 2003b; Hsu et al., 2003; Keck et al., 2004; Op De Beeck et al., 2004). Conformation-dependent human monoclonal antibodies have also led to the identification of three immunogenic domains in E2 with neutralizing antibodies being restricted to two of these domains (Keck et al., 2004). Whether E2 domains identified with these monoclonal antibodies are similar to the antigenic structural and functional domains of the envelope protein E of the flaviviruses (Rey et al., 1995) remains to be determined.

Conclusion and future directions

Studies of the biogenesis of HCV envelope glycoproteins have shown the pivotal role of the transmembrane domains in the assembly of a noncovalent E1E2 heterodimer in the ER. The HCVpp model has allowed the investigation of the role of E1E2 heterodimer in virus entry, the identification of functional regions in HCV envelope glycoproteins and the validation of potential receptors. The recent development of the HCVcc system is an additional tool to validate the data generated with HCVpp. Entry is an essential step in the life cycle of a virus, which can potentially be blocked by neutralizing antibodies or antiviral drugs that target the envelope proteins of the virus. Understanding the viral and cellular...
components involved in HCV invasion into the host cell, combined with a comprehension of the mechanisms that govern this process, should therefore open the possibility of developing new therapeutic approaches, as shown with cyanovirin-N (Helle et al., 2006).

In addition to their role in virus entry, HCV envelope glycoproteins are also supposed to be involved in other steps of HCV life cycle, e.g., particle assembly. Studying other functions of HCV glycoproteins in the context of its life cycle is now possible with the development of the HCVcc system. Understanding the role of HCV envelope glycoproteins in virus assembly will be a major goal in the coming years. Finally, obtaining a high-resolution structure of HCV envelope glycoproteins will also be essential to understand the fusion mechanism of this virus.

Acknowledgments
We thank Sophana Ung for preparing the illustrations. Our research was supported by EU grant QLRT-2000–01120 and QLRT-2001–01329 and grants from the “Agence Nationale de Recherche sur le Sida et les hépatites virales” (ANRS), INSERM “ATC-Hépatite C” and the “Association pour la Recherche sur le Cancer” (ARC). JD is an international scholar of the Howard Hughes Medical Institute.

References
transmembrane domain of hepatitis C virus glycoprotein E1 is a signal for static retention in the endoplasmic reticulum. J. Virol. 73, 2641–2649.


neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C Virus infection. J. Virol. 79, 6023–6034.


cell culture system that efficiently replicates the virus. J. Virol. 80, 2832–2841.
hepatitis C virus glycoprotein-mediated viral infection. J. Virol. 78, 1448–1455.